# AN2 Therapeutics (ANTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ANTX
## Company Profile
- Ticker: ANTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Infectious Disease
## Stock Data
- Close: 6.28 USD
- Market cap: 146585775.27 USD
- Last updated: 2026-08-12
## Business Overview
### Boron-Based Drug Development
AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology.
### Epetraborole in Polycythemia Vera
AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent polycythemia vera. The program will evaluate whether the drug can maintain hematocrit control and reduce phlebotomy frequency.
### Epetraborole in M. abscessus
Epetraborole is also being studied in an investigator-initiated Phase 2 trial for *Mycobacterium abscessus* lung disease. The study is intended to establish clinical proof of concept and inform a potential pivotal program.
### Chagas Disease Program
AN2-502998 is an oral CPSF3 inhibitor for chronic Chagas disease. Its development is supported by translational efficacy work in naturally infected non-human primates.
### Oncology Discovery Pipeline
AN2 has declared a boron-containing ENPP1 inhibitor for solid tumors and is also researching PI3Kα and other difficult-to-drug targets in oncology and bone disorders.
## Why The Stock Is Moving

Following the latest company update, “AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights”, ANTX closed up 6.98% at $6.28 on Aug 12, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- IND filing for the EBO-PV-201 study of epetraborole in polycythemia vera in the third quarter of 2026.
- Initiation of Phase 2 enrollment in EBO-PV-201 in the fourth quarter of 2026.
- Initiation of a Phase 2 proof-of-concept study of AN2-502998 in chronic Chagas disease in late 2026.
- Initial Part 1 data from EBO-PV-201 during 2027.
- Topline results from the investigator-initiated Phase 2 epetraborole study in *M. abscessus* lung disease in late 2027.

## Recent News
- 2026-08-11 20:00 EST — [AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-second-quarter-2026-financial-results-and-recent-busine-0c19bdf7) — Source: AN2 Therapeutics
- 2026-06-04 11:00 EST — [AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-positive-enabling-data-supporting-advancement-of-oral-an2-502998-to-phase-2-study-for-chronic-chagas-disease) — Source: AN2 Therapeutics
- 2026-05-21 11:00 EST — [AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-present-at-2026-jefferies-global-healthcare-conference) — Source: AN2 Therapeutics
- 2026-05-11 20:01 EST — [AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights](https://biopharmsignal.com/news/ANTX/an2-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-and-scientific-highlights) — Source: AN2 Therapeutics
- 2026-05-07 20:01 EST — [AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum](https://biopharmsignal.com/news/ANTX/an2-therapeutics-to-participate-in-2026-stifel-virtual-targeted-oncology-forum) — Source: AN2 Therapeutics